Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 124,775	$ 208,892
Short-term investments	42,086	50,441
Accounts receivable	33,729	22,934
Inventories, net	35,201	34,394
Prepaid clinical development costs	1,026	1,138
Other prepaid and current assets	9,866	11,173
Total current assets	246,683	328,972
Restricted cash	0	50,000
Property and equipment, net	164	664
Right of use operating lease assets	1,036	1,898
Intangible assets	56	56
Total assets	247,939	381,590
Current liabilities:
Accounts payable	23,040	17,559
Accrued clinical development costs	5,426	7,013
Other accrued liabilities	35,191	30,410
Revenue interest liability	24,760	11,295
Deferred revenue from collaborations	3,507	5,683
Operating lease liabilities	384	1,392
Total current liabilities	92,308	73,352
Convertible notes, net of issuance costs	259,899	258,280
Revenue interest liability	218,845	245,744
Operating lease liabilities	665	524
Deferred revenue from collaborations	0	634
Total liabilities	571,717	578,534
Commitments and contingencies (Note 5)
Stockholders’ (deficit) equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of December 31, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 240,000,000 shares authorized as of December 31, 2022 and 120,000,000 shares authorized as of December 31, 2021; 76,564,396 shares issued at December 31, 2022 and 62,873,694 shares issued at December 31, 2021	75	61
Additional paid-in capital	1,071,183	964,401
Treasury stock, at cost; 1,994,198 shares at December 31, 2022 and December 31, 2021	(54,998)	(54,998)
Accumulated other comprehensive loss	(2)	(31)
Accumulated deficit	(1,340,036)	(1,106,377)
Total stockholders' deficit	(323,778)	(196,944)
Total liabilities and stockholders' deficit	$ 247,939	$ 381,590